Latest

Understand ALK fusion testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

ALK Fusion Test for Lung Cancer: Gene Fusion, Positive Result, and Molecular Meaning

Understand BRAF V600E testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

BRAF V600E Test for Lung Cancer: Mutation Status, Positive Result, and Molecular Meaning

Learn how the carcinoembryonic antigen (CEA) test is used in lung cancer, what high levels can mean, common non-cancer causes, reference ranges, and why serial trends matter.

CEA Test for Lung Cancer: Tumor Marker Monitoring, High Levels, and Result Meaning

Learn how the cytokeratin 19 fragment 21-1 (CYFRA 21-1) test is used in lung cancer, what high levels can mean, common non-cancer causes, reference ranges, and why serial trends matter.

CYFRA 21-1 Test for Lung Cancer: Tumor Marker Levels and Disease Monitoring

Understand EGFR exon 20 insertion testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

EGFR Exon 20 Insertion Test: Lung Cancer Mutation Status and Molecular Meaning

Understand EGFR mutation testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

EGFR Mutation Test for Lung Cancer: Exon 19, L858R, T790M, Mutation Status, and...

Diagnostics

Home Diagnostics Page 52

Learn how FGFR2 and FGFR3 genetic testing detects cancer mutations and fusions, what positive or negative results mean, and how findings may guide targeted therapy.

FGFR2 and FGFR3 Genetic Test: Cancer Mutations, Fusions, and Results

Understand FH genetic testing for hereditary leiomyomatosis and renal cell cancer, including who should test, result meanings, kidney surveillance, and family risk.

FH Genetic Test: Hereditary Leiomyomatosis, Renal Cell Cancer, and Results

Learn what FLCN genetic testing shows for Birt-Hogg-Dubé syndrome, including kidney cancer surveillance, lung cyst risks, result meanings, and family testing.

FLCN Genetic Test: Birt-Hogg-Dube Syndrome, Kidney Cancer, and Results

Learn how the FLT3 mutation test guides AML risk assessment, targeted treatment, transplant planning, relapse testing, and interpretation of ITD and TKD results.

FLT3 Mutation Test: AML, Leukemia Risk, and Treatment Results

Understand HER2 and ERBB2 testing in breast, gastric, lung, and other cancers, including IHC, ISH, mutations, targeted therapy, and result interpretation.

HER2/ERBB2 Test: Breast, Gastric, Lung Cancer, and Targeted Therapy Results

Learn how hereditary cancer genetic panels test multiple risk genes, who should be tested, what positive, negative, and VUS results mean, and how findings guide care.

Hereditary Cancer Genetic Panel Test: Cancer Risk Genes and Results

Learn how IDH1 and IDH2 mutation testing guides diagnosis and treatment in glioma, AML, and cholangiocarcinoma, including positive, negative, and targeted therapy results.

IDH1 and IDH2 Mutation Test: Brain Cancer, Leukemia, Cholangiocarcinoma, and Results

Learn how JAK2 mutation testing supports diagnosis of polycythemia vera, essential thrombocythemia, and myelofibrosis and how positive, negative, and low-level results are interpreted.

JAK2 Mutation Test: Myeloproliferative Neoplasm, Blood Cancer, and Results

Learn how KIT mutation testing guides GIST therapy, identifies selected melanoma targets, supports systemic mastocytosis diagnosis, and clarifies positive, negative, and low-level results.

KIT Mutation Test: GIST, Melanoma, Mast Cell Disease, and Results

Learn how KRAS mutation testing guides treatment in colorectal, lung, and pancreatic cancer and how to interpret G12C, other variants, negative results, and repeat testing.

KRAS Mutation Test: Colon, Lung, Pancreatic Cancer, and Results

Learn how liquid biopsy and ctDNA testing find tumor mutations, guide targeted therapy, assess resistance and MRD, and why negative or low-level plasma results need careful interpretation.

Liquid Biopsy Cancer Test: ctDNA, Tumor Mutations, and Results

Learn how Lynch syndrome testing for MLH1, MSH2, MSH6, PMS2, and EPCAM works, how tumor screening differs from germline testing, and what positive, negative, and uncertain results mean.

Lynch Syndrome Genetic Test: MLH1, MSH2, MSH6, PMS2, EPCAM, and Results

Learn how MEN1 genetic testing confirms multiple endocrine neoplasia type 1, who should be tested, what positive and negative results mean, and how surveillance protects patients and relatives.

MEN1 Genetic Test: Multiple Endocrine Neoplasia Type 1 and Results

Learn how MET exon 14 skipping testing finds an actionable lung cancer driver, why DNA and RNA methods differ, and how positive, negative, plasma, treatment, and resistance results are interpreted.

MET Exon 14 Skipping Test: Lung Cancer, Targeted Therapy, and Results

Learn how MSI and dMMR testing guides cancer immunotherapy and Lynch syndrome evaluation, including IHC patterns, PCR, NGS, reflex testing, and discordant results.

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR) Test: Cancer Immunotherapy,...

Learn how minimal residual disease (MRD) tests detect tiny amounts of cancer, what positive and negative results mean, and how testing may guide recurrence risk and follow-up.

Minimal Residual Disease (MRD) Test: Cancer Recurrence Risk and Results

Learn what an MLH1 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MLH1 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how the MPL mutation test helps evaluate high platelets and myeloproliferative neoplasms, including positive, negative, VAF, treatment, and follow-up results.

MPL Mutation Test: Myeloproliferative Neoplasm, Platelets, and Results

Learn what an MSH2 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH2 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn what an MSH6 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH6 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

1...515253...93 Page 52 of 93